Relevant bibliographies by topics / Erectile dysfunction drugs

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters

Academic literature on the topic 'Erectile dysfunction drugs'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Erectile dysfunction drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Erectile dysfunction drugs"

1

Greener, Mark. "Erectile dysfunction drugs." Inpharma Weekly &NA;, no. 1203 (September 1999): 3–4. http://dx.doi.org/10.2165/00128413-199912030-00004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Terzic, Branka, Srdjan Markovic, Jelena Grujic, and Ljiljana Djukic. "Cardiovascular drugs and erectile dysfunction." Hospital Pharmacology - International Multidisciplinary Journal 1, no. 3 (2014): 174–79. http://dx.doi.org/10.5937/hpimj1403174t.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Saffon Cuartas, José Pablo, Carolina Sandoval-Salinas, Juan M. Martínez, and Héctor A. Corredor. "Treatment of Priapism Secondary to Drugs for Erectile Dysfunction." Advances in Urology 2019 (August 22, 2019): 1–4. http://dx.doi.org/10.1155/2019/6214921.

Full text
Abstract:
Priapism may present as a side effect in patients treated with medications for erectile dysfunction, in which it should be controlled in a timely manner to avoid complications. There is little information regarding the use of local measures for the treatment of this condition. This study was done with the objective to describe the management of priapism secondary to erectile dysfunction drugs in a cohort of men. Records of emergencies and adverse events were reviewed by two researchers to identify patients diagnosed with erectile dysfunction who received oral or intracavernosal drugs for their illness and presented priapism. Sociodemographic data, clinical background, and information on the duration, management, and evolution of the priapism were extracted. Priapism incidence, percentage of improvement by type of treatment subgroups, and frequency of complications were estimated. 698 patients were treated with PDE-5 inhibitors and 2,135 with intracavernosal drugs. Thirty-one patients (1.4%) reported at least one priapism event during treatment, all with intracavernosal drugs. Treatment with local measures was effective for 10 (32.2%) patients, 1 (3.2%) required terbutaline, 19 (61.2%) used intracavernosal etilefrine, and 1 (3.2%) required drainage and flushing of cavernous bodies. After the priapism episode, 3 (9.6%) patients required an increased dose of the drug in order to achieve satisfactory erection. The results suggest that in men treated for priapism secondary to the use of sexual impotence drugs, initial treatment with local measures and etilefrine can achieve detumescence, decreasing the need for invasive procedures or surgery as a first-line therapy alternative. It is necessary to carry out research studies to confirm this hypothesis.
APA, Harvard, Vancouver, ISO, and other styles
4

MONTORSI, F. "WS027 Oral drugs for erectile dysfunction." Journal of the European Academy of Dermatology and Venereology 9 (September 1997): S84. http://dx.doi.org/10.1016/s0926-9959(97)89186-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Belavic, Jennifer M. "A look at erectile dysfunction drugs." Nursing Made Incredibly Easy! 8, no. 1 (January 2010): 13–15. http://dx.doi.org/10.1097/01.nme.0000366095.77674.c5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

EISENBERG, JEFFREY S. "CVD Drugs, Lifestyle Fix Erectile Dysfunction." Internal Medicine News 44, no. 16 (October 2011): 48. http://dx.doi.org/10.1016/s1097-8690(11)70841-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hornbrook, M. C., and J. Holup. "Insurance Coverage for Erectile Dysfunction Drugs." Clinical Pharmacology & Therapeutics 89, no. 1 (January 2011): 19–21. http://dx.doi.org/10.1038/clpt.2010.265.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Turkoski, Beatrice B. "Drugs Used to Treat Erectile Dysfunction." Orthopaedic Nursing 27, no. 3 (May 2008): 201–4. http://dx.doi.org/10.1097/01.nor.0000320552.30020.7b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

&NA;. "Drugs Used to Treat Erectile Dysfunction." Orthopaedic Nursing 27, no. 3 (May 2008): 205–6. http://dx.doi.org/10.1097/01.nor.0000320553.07149.6d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Blanker, Marco H., and Arianne P. Verhagen. "Lipid-lowering drugs and erectile dysfunction." Family Practice 19, no. 5 (October 2002): 567. http://dx.doi.org/10.1093/fampra/19.5.567.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Erectile dysfunction drugs"

1

Kunelius, P. (Pekka). "Sexual dysfunction:the roles of yohimbine hydrochloride and intracavernosal vasoactive drugs in the treatment of erectile dysfunction, the effect of transurethral resection of prostate on sexual functions and the impact of dihydrotestosterone on andropausal symptoms." Doctoral thesis, University of Oulu, 1999. http://urn.fi/urn:isbn:9514253868.

Full text
Abstract:
Abstract Altogether 406 patients were included in five studies, and all patients were examined and controlled in the Oulu University Hospital during the years 1991–1998. Twenty-nine patients with mixed-type erectile dysfunction (ED) were recruited into a randomized, controlled, double-blind crossover comparison of placebo and high-dose yohimbine hydrochloride (36 mg per day orally). Positive clinical responses were obtained in 44% of the patients during yohimbine treatment and in 48% during placebo treatment. Thirty patients with ED underwent an intracavernosal injection test (ICI) using three different active agents (prostaglandin E1(PGE1), papaverine hydrochloride (PV), moxisylyte (MS)) and physiological saline. PGE1 produced significantly better rigidity than either PV or MS. Sixty-nine patients with ED who had started ICI therapy with PGE1 at least three years previously were invited to a control examination to find out the long-term outcome of this treatment and to evaluate the patients' overall satisfaction with their sexual life. 46.4% of the patients had discontinued PGE1 therapy, the mean time of using PGE1 having been 23.3 months (range 0–48 months). 34.8% of the patients reported that their own spontaneous erections had improved during the PGE1 therapy. The sexual functions of 155 patients with benign prostatic hyperplasia (BPH) were evaluated before TURP and 6 and 12 months afterwards with questionnaires. Only 26% of the patients had completely satisfactory erections before TURP, while 22% had satisfactory erections 6 months later and 24% 12 months later. The majority of patients (about 70%) were satisfied with their sexual life both before and after the procedure. 123 men with symptoms of andropause participated in a randomized, placebo-controlled study to assess the effects of dihydrotestosterone (DHT) gel in men with andropausal symptoms. The drug was administered transdermally once a day during six months. Early morning erections improved significantly (p < 0.003) in the DHT group by the three-month control, the ability to maintain erections was better, and there was also a positive effect on libido. In the patients with a elevated (> 12) international index of the prostatic symptoms score (I-PSS) before DHT treatment, I-PSS decreased from 17.7 to 12.3 points. As a conclusion yohimbine hydrochloride is no better than placebo in the treatment of patients with mixed-type ED. PGE1, PV and MS are well tolerated, and PGE1 was shown to be the most effective drug of the three. ICI therapy with PGE1 in long-term use is safe and effective. Sexual functions in men did not change after TURP, and this group of aging men were fairly satisfied with their sexual life despite of the fact that they had some ED and one third of the patients had not had intercourse during the previous year. Transdermal administration of DHT in aging men improves sexual function.
APA, Harvard, Vancouver, ISO, and other styles
2

Skeldon, Sean Christopher Toshiaki. "Erectile dysfunction medications : a gateway drug for men." Thesis, University of British Columbia, 2016. http://hdl.handle.net/2429/56653.

Full text
Abstract:
Background – Erectile dysfunction (ED) has been described as providing a ‘window of curability’ for men at risk of future cardiovascular disease, however there is little evidence on the relationship between erectile dysfunction and modifiable cardiometabolic risk factors. The primary objectives of this thesis were to: 1) determine whether men with ED have a higher risk of having an undiagnosed cardiometabolic risk factor (hypertension, hypercholesterolemia and diabetes), and 2) determine whether the prescription of a phosphodiesterase type 5 inhibitor (PDE5i) for ED leads to an increase in the diagnosis and treatment of these risk factors. Methods – This thesis comprised of two original studies. The first, a cross-sectional analysis using a nationally representative survey from the United States. The second, a population-based empirical study of changes in drug utilization for cardiometabolic risk factors following PDE5i prescription in British Columbia. An individual-level time series analysis with switching replications was utilized for this analysis. Results – Men with ED were found to have double the odds of having undiagnosed diabetes compared to those without ED. This was most significant among middle-aged men (ages 40-59 years), as the predicted probability of having undiagnosed diabetes increased from 1 in 50 in men without ED to 1 in 10 in men with ED. Among men aged 40 to 59 years old in British Columbia, we found a sudden increase in prescriptions for antihypertensives (28 per 1,000), statins (15 per 1,000), and antidiabetics (18 per 1,000) in the 90 days following a new prescription for a PDE5i. For both hypercholesterolemia and diabetes, relevant screening tests performed in the 30 days following PDE5i prescription were responsible for this change. This increase was followed by a significant declining trend in prescriptions for all three drugs. Conclusions – Men with ED have an increased risk for undiagnosed cardiometabolic risk factors. PDE5is can act as a ‘gateway drug’ for men to be newly treated for these risk factors provided physicians perform the requisite screening investigations. Increased education and awareness of this relationship among both patients and physicians is critical for exploiting the potential for preventing future cardiovascular disease.
Medicine, Faculty of
Population and Public Health (SPPH), School of
Graduate
APA, Harvard, Vancouver, ISO, and other styles
3

Ekman, Elisabet. "Pharmacovigilance : spontaneous reporting in health care." Doctoral thesis, Linnéuniversitetet, Institutionen för medicin och optometri (MEO), 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-26820.

Full text
Abstract:
Pharmacovigilance in healthcare is essential for safe drug treatment. Spontaneous reporting is the most common source of information in the context of implementing label changes and taking a drug off the market. However, underreporting is found to be very prevalent. One way to decrease underreporting is to include different categories of healthcare professionals in such reporting and to investigate attitudes towards and incentives for reporting adverse drug reaction (ADR)s. As nurses form the largest group of health professionals, a sample of nurses were allowed and encouraged to report ADR during a 12 month period after they had received training in pharmacovigilance. A questionnaire posted to physicians and nurses investigated their knowledge and attitudes towards reporting. Spontaneous reports of torsade de pointes (TdP) and erectile dysfunction (ED) were scrutinized with respect to the reported drugs, risk factors and if the reaction was listed in the summary of product characteristics (SPC). After training, the nurses produced relevant reports and three years after the introduction of nurses in the reporting scheme, more than half of the responding nurses were aware of their role as reporters. Both nurses and physicians stated that the most important factor for reporting a suspected ADR was the severity of the ADR and an ADR arising in response to a newly approved drug. A web-based reporting system was deemed to facilitate the reporting. In spontaneous reports of TdP, citalopram was reported as a suspected drug. However, neither QT prolongations, nor TdP, were labelled in the SPC. ED was reported for all antihypertensive drugs including angiotensin II type I blockers. A positive information component (IC), assessing the disproportionality between the observed and the expected number of reports, was found indicating that ED was reported more often in association with antihypertensive drug classes, except for angiotensinconverting enzyme inhibitors. This thesis demonstrates the importance of pharmacoviglilance in healthcare in terms of capturing new signals. By including nurses as reporters, the overall safety of drugs might improve. Information and education are needed to secure safe treatment when applying drugs.
APA, Harvard, Vancouver, ISO, and other styles
4

Lebel, Philippe. "Développement de méthodes de dépistage des médicaments de contrefaçon et des produits adultérés par LC-MS/MS." Thèse, 2014. http://hdl.handle.net/1866/11910.

Full text
Abstract:
Ce projet de maitrise implique le développement et l’optimisation de deux méthodes utilisant la chromatographie liquide à haute performance couplée à la spectrométrie de masse en tandem (HPLC-MS/MS). L'objectif du premier projet était de séparer le plus rapidement possible, simultanément, 71 médicaments traitant la dysfonction érectile (ED) et 11 ingrédients naturels parfois retrouvés avec ces médicaments dans les échantillons suspectés d’être adultérés ou contrefaits. L'objectif du deuxième projet était de développer une méthode de dépistage permettant l'analyse rapide simultanée de 24 cannabinoïdes synthétiques et naturels pour une grande variété d'échantillons tels que les mélanges à base de plantes, des bâtons d'encens, de sérums et de cannabis. Dans les deux projets, la séparation a été réalisée en moins de 10 min et cela en utilisant une colonne C18 à noyau solide 100 x 2,1 mm avec des particules de 2,6 µm de diamètre couplée à un système MS avec trappe ionique orbitale fonctionnant en électronébulisation positive. En raison du nombre élevé de composés dans les deux méthodes et de l’émergence de nouveaux analogues sur le marché qui pourraient être présents dans les échantillons futurs, une méthode de dépistage LC-MS/MS ciblée/non-ciblée a été développée. Pour les deux projets, les limites de détection étaient sous les ng/mL et la variation de la précision et de l’exactitude étaient inférieures de 10,5%. Le taux de recouvrement à partir des échantillons réels variait entre 92 à 111%. L’innovation des méthodes LC-MS/MS développées au cours des projets est que le spectre de masse obtenu en mode balayage lors de l'acquisition, fournit une masse exacte pour tous les composés détectés et permet l'identification des composés initialement non-ciblés, comme des nouveaux analogues. Cette innovation amène une dimension supplémentaire aux méthodes traditionnellement utilisées, en permettant une analyse à haute résolution sur la masse de composés non-ciblés.
This master’s project involved the development and optimization of two rapid liquid chromatography tandem mass spectrometry (LC-MS/MS) methods. The objective of the first project was to simultaneously separate, as rapidly as possible, 71 erectile dysfunction (ED) treatment drugs and 11 natural ingredients sometimes found alongside ED drugs present in suspected adulterated or counterfeit samples. The objective of the second project was to develop a screening method allowing rapid, simultaneous analysis of 24 synthetic and natural cannabinoids for a wide variety of samples such as herbal smoking mixtures, incense sticks, serums and Cannabis plant material. In both projects, the separations were achieved in ≤ 10 min using 2.6 µm fused-core C18 particles packed into a 100 x 2.1 mm column coupled to an LTQ Orbitrap XL mass spectrometer operated in positive electrospray mode. Because of the very high number of compounds in both methods and the knowledge that future analogues are always immerging on the market that could thus be present in samples, a targeted/untargeted LC-MS/MS screening method was developed. For both projects, detection limits were in the sub ng/mL range and intra- and inter-assay precisions were below 10.5%. Recovery from real samples ranged from 92 to 111%. The innovation of the developed LC-MS/MS methods is that the full scan event in the MS acquisition provides accurate masses for all detected species and thus allows post-analysis identification of initially untargeted compounds, i.e., the immerging analogues. This innovation adds an additional dimension to traditional MS/MS methods, allowing high mass resolution of untargeted compounds.
APA, Harvard, Vancouver, ISO, and other styles
5

Schneider, Hrouzková Alexandra. "Sexualita uživatelů marihuany." Doctoral thesis, 2018. http://www.nusl.cz/ntk/nusl-379333.

Full text
Abstract:
Objectives: As part of the research issue, we tracked six sub-objectives of the research. The first objective of the research was to describe the sexual behavior of marihuana users in selected areas of sexuality based on data obtained from the questionnaire survey. The presented research was aimed at heterosexual men who regularly use marihuana at a frequency of once a week to daily. The second objective was to find a link between the frequency of marihuana use and selected areas of sexuality. The third objective of our work was to find a link between the length of marihuana use and selected areas of sexuality. The fourth objective of the research was to find a link between the influence of the use of other psychoactive substances on marihuana users in selected areas of sexuality. The fifth objective of our work was to find out the links between tobacco use in a marihuana user group and selected areas of sexuality. The sixth objective was to find a link between the use of marihuana and erectile function, respectively dysfunctions, according to The International Index of Erectile Function (IIEF-5). Methods: For research purposes, we chose a quantitative type of study. The sample comprised 392 respondents, regular heterosexual marihuana users using marihuana at least once a week. A non-standardized...
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Erectile dysfunction drugs"

1

Melchiode, Gerald A. Beyond viagra: A commonsense guide to building a healthy sexual relationship for both men and women. New York: Henry Holt, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Botz-Bornstein, Thorsten. The philosophy of Viagra: Bioethical responses to the viagrification of the modern world. Amsterdam: Rodopi, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sex, The Heart and Erectile Dysfunction. Informa Healthcare, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Katritsis, Demosthenes G., Bernard J. Gersh, and A. John Camm. Cardiovascular drugs. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199685288.003.1900_update_002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

McMahon, Chris G. Ejaculatory disorders. Edited by David John Ralph. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0105.

Full text
Abstract:
Ejaculatory/orgasmic disorders are common male sexual dysfunctions, and include premature ejaculation (PE), inhibited ejaculation, anejaculation, retrograde ejaculation, and anorgasmia.Premature ejaculation management is largely dependent upon aetiology. Life-long PE is best managed with PE pharmacotherapy (selective serotonin re-uptake inhibitor [SSRI] and/or topical anaesthetics). The management of acquired PE is aetiology-specific and may include erectile dysfunction (ED) pharmacotherapy in men with co-morbid ED. Behavioural therapy is indicated when psychogenic or relationship factors are present and is often best combined with PE pharmacotherapy in an integrated treatment programme. Delayed ejaculation, anejaculation, and/or anorgasmia may have a biogenic and/or psychogenic aetiology. Men with age-related penile hypoanesthesia should be educated, reassured, and instructed in revised sexual techniques which maximize arousal. No drugs have yet been approved by regulatory agencies for this purpose, and most drugs identified for potential use have limited efficacy, impart significant side effects, or are considered experimental in nature.
APA, Harvard, Vancouver, ISO, and other styles
6

Yarnell, Eric. Botanicals (Adaptogens and Others) that Support or Stimulate Desire (DRAFT). Edited by Madeleine M. Castellanos. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190225889.003.0023.

Full text
Abstract:
Botanical medicines can play an important role in helping men and women with sexual dysfunction. Marketing hype has distorted their role, and illegal adulteration of herbal products with unlabeled phosphodiesterase type 5-inhibiting drugs is a rampant problem in the marketplace. Research most validates the traditional use of Panax ginseng (Asian ginseng) root, Pausinystalia yohimbe (yohimbe) bark, Epimedium spp (horny goat weed) leaf and stem, and Crocus sativus (saffron) stamen for enhancing libido and erectile function. Withania somnifera (ashwagandha) root, Turnera diffusa (damiana) leaf, and Tribulus terrestris (caltrop vine) fruit are less well studied but still have a strong reputation in traditional medicine as aphrodisiacs. Clinical use of these herbs is discussed with case examples. The problem with biopiracy of traditional aphrodisiacs from the Global South is also reviewed.
APA, Harvard, Vancouver, ISO, and other styles
7

Veatch, Robert M., Amy Haddad, and E. J. Last. Justice. Edited by Robert M. Veatch, Amy Haddad, and E. J. Last. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190277000.003.0006.

Full text
Abstract:
This chapter considers the pharmacist’s duty based on the principle of justice. It addresses issues of allocation of health resources. It first addresses allocations among patients, then the tension between the interests of patients and others, and finally justice in broad issues of public policy. The cases deal with the pharmacist’s conflicts between serving a patient in crisis and a hypochondriac, funding compassionate use pharmaceuticals, the tension between the interests of a patient and her husband, obesity and the allocation of a scarce drug, payment for erectile dysfunction therapy, and the conflict between giving attention to a patient in great need and a promise to give attention to another less urgent patient.
APA, Harvard, Vancouver, ISO, and other styles
8

Muneer, Asif, and David Ralph. Priapism. Edited by David John Ralph. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0106.

Full text
Abstract:
Priapism is rare and is a medical emergency. Ischaemic priapism is the commonest subtype with haematological abnormalities, psychotropic or recreational drug use and malignancy being the other common aetiologies. Emergency decompression of this compartment syndrome is required to preserve cavernosal smooth muscle function and this should ideally be performed as soon as possible. The degree of resultant erectile dysfunction is related to the duration of the priapism. Non-ischaemic priapism is an unregulated inflow of arterial blood, often as a result of perineal trauma and a lacerated cavernosal vessel. Selective arterial embolization should be performed and results are usually excellent. The final subtype is stuttering priapism, the cause of which is often unknown and a variety of methods will be discussed for its treatment.
APA, Harvard, Vancouver, ISO, and other styles
9

Botz-Bornstein, Thorsten. Philosophy of Viagra: Bioethical Responses to the Viagrification of the Modern World. Rodopi, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Erectile dysfunction drugs"

1

Alphs, Hannah H., and Kevin T. McVary. "Drugs that Affect Sexual Function." In Contemporary Treatment of Erectile Dysfunction, 81–91. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60327-536-1_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Israel, Jonathan, and Eric L. Laborde. "Alternative and Internet Drugs that Affect Sexual Function." In Contemporary Treatment of Erectile Dysfunction, 137–48. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-31587-4_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Eardley, Ian. "Pharmacology of drugs used for the treatment of erectile dysfunction." In Male Sexual Dysfunction, 48–55. Chichester, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118746509.ch6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Buvat, Jacques, and Antoine Lemaire. "Intraindividual Comparative Studies on Efficacy, Safety, and Side-Effects of Different Vasoactive Drugs in Erectile Dysfunction." In Penile Disorders, 197–215. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60548-2_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Garcia, Francisco J., Eric Chung, and Gerald Brock. "Drug therapy for erectile dysfunction." In Male Sexual Dysfunction, 172–93. Chichester, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118746509.ch19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Papademetriou, Vasilios, Antonios Lazaridis, Eirini Papadopoulou, Theodosia Papadopoulou, and Michael Doumas. "Antihypertensive Drug Therapy and Erectile Dysfunction." In Erectile Dysfunction in Hypertension and Cardiovascular Disease, 175–84. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-08272-1_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Padma-Nathan, Harin. "Transurethral Drug Therapy for Erectile Dysfunction." In Penile Disorders, 159–62. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60548-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Griebenow, Nils, Helmut Haning, and Erwin Bischoff. "Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction." In Analogue-Based Drug Discovery II, 135–72. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2010. http://dx.doi.org/10.1002/9783527630035.ch6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yamada, Koichiro, Toshiaki Sakamoto, Kenji Omori, and Kohei Kikkawa. "The Discovery of Stendra™(Avanafil) for the Treatment of Erectile Dysfunction." In Successful Drug Discovery, 61–86. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2015. http://dx.doi.org/10.1002/9783527678433.ch4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ückert, Stefan, and Christian G. Stief. "Treatment of Erectile Dysfunction and Lower Urinary Tract Symptoms by Phosphodiesterase Inhibitors." In Phosphodiesterases as Drug Targets, 307–22. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-17969-3_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Erectile dysfunction drugs' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography